EASD 2025 Resource Hub – September 17 2025

Welcome to our resource hub for EASD 2025! This is a one-stop-shop for all your EASD 2025 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Important Conference Information. For those who cannot travel to Vienna, the conference will continue to be held in a traditional format, with the excellent “plus” that everything is recorded and goes on the EASD website each evening. We have great appreciation for EASD’s virtual platform given the superb performance of the platform over multiple decades and given EASD’s longtime practice of recording sessions. See the conference website and the agenda, register here, and read our preview here.

Useful Conference Links

Day-of Conference Reports

Diabetes Therapy Highlights

Profs. Heerspink, Roden, and Bozkurt highlight the potential for SGLT-2 inhibitor and GLP-1 RA combination therapy for cardiorenal protection
Revolutionizing cardiometabolic health: Novo Nordisk’s industry symposium focuses on the kidney, liver, and weight management
Lilly symposium highlights the evolving and crucial role of CVOTs in T2D management
Amgen’s symposium highlights the roles of GIP receptor agonism/antagonism and once-monthly MariTide in metabolic diseases; Dr. Donna Ryan: a “golden age” of obesity development
Post-hoc analysis of SOUL trial finds CV benefits of Rybelsus (oral semaglutide) regardless of baseline A1c or BMI
Full phase 2 results of dual GLP-1/GIP RA HRS9531 for overweight or obesity without T2D
The role of incretin-based treatments in T1D management
ELSA study shows acceptability and feasibility of general population screening for pre-symptomatic T1D among children in the UK
Post-hoc analysis of phase 3 REDEFINE-1 trial: Long-acting amylin analog cagrilintide confers greater weight loss (12%) than placebo (2.3%)
Discussion with Dr. Alice Cheng, Prof. Francesco Giorgino, and Prof. Ezio Bonifacio on population-wide, age-indiscriminate screening for T1D
Insulin therapy and cardiorenal outcomes in T2D: A pooled analysis of CANVAS and CREDENCE
Phase 3 study finds A1c reduction and potential cardiorenal protection with berberine ursodeoxycholate
Full results of phase 3 ATTAIN-1 trial: Lilly’s once-daily GLP-1 orforglipron demonstrates 11% weight loss in people with obesity
Phase 3 REDEFINE 2 trial: CagriSema significantly increases Time in Range in people with obesity and T2D, per secondary analysis
TIRTLE1 T1D trial shows that Lilly’s once-weekly GLP-1/GIP tirzepatide reduces weight (9%) and insulin dose (33%) and improves body composition
Oral quadruple agonist NA-831 for obesity: Topline phase 2 results suggest weight loss without muscle loss and GI-related side effects
Incretin-associated sarcopenia: Does it matter which treatment?
Phase 2b COURAGE trial: Regeneron’s trevogrumab help preserve 50-80% of lean mass lost with semaglutide alone
Amycretin demonstrates favorable pharmacokinetics, safety, and tolerability in people with renal impairment
Precision medicine in T2D: Targeting GLP-1 RAs and SGLT-2 inhibitor combination treatment for kidney protection
Phase 2b PROGRESS trial results show AAK1 inhibitor pilavapadin (LX9211) reduces pain in DPN; findings support phase 3 trial for 10 mg dose
Additional CATALYST trial insights and perspectives on the current hypercortisolism diagnostic cutoff from UNC’s Dr. John Buse
Pooled analysis of SOUL, FLOW, and STRIDE: Semaglutide reduces major adverse limb events by 30% compared to placebo
Trends of SGLT-2 inhibitor use in T2D in the UK: Up to 90% with T2D and CKD eligible, but uptake not yet optimal
Real-world study finds semaglutide is associated with 23% reduced MACE compared to dulaglutide in people with T2D and CVD
Zealand’s once-weekly dual GLP-1/GLP-2 RA dapiglutide confers up to 8% weight loss at Week 13
Full results of SURPASS-CVOT: Tirzepatide reduces MACE numerically by 8%
Additional results of SURPASS-CVOT: Tirzepatide significantly reduces weight and glycemic outcomes
SURPASS-PEDS: Tirzepatide dropped A1c by 2.3 percentage points from undisclosed baseline; first GLP-1 RA to demonstrate clinically meaningful weight loss (-9.1%) in youth with T2D
STEP UP prespecified post-hoc studies reveal positive effects on body composition, proximal muscle strength, and control of eating with semaglutide 7.2 mg
EASD-EASL joint symposium: Bridging the gap with improved screening and the use of combination therapies
Prespecified analysis of phase 2 CONFIDENCE trial: simultaneous use of finerenone (Bayer’s Karendia) and empagliflozin (BI/Lilly’s Jardiance) prompted far better outcomes while addition of GLP-1 yielded nothing additional
New paths for old friends: Potential new roles for GLP-1 RAs and SGLT-2 inhibitors
INNODIA’s phase 2 MELD-ATG trial finds low-dose ATG significantly preserves C-peptide levels in young individuals with new-onset T1D
In Ver-A-T1D trial, verapamil confers non-statistically significant preservation in C-peptide in new-onset T1D
“There's no insulin like your own”: Two-year outcomes of the BANDIT trial demonstrate JAK inhibitor baricitinib preserves C-peptide
Do we need really need a large outcome trial to prove the cardiorenal benefits of SGLT-2 inhibitor and GLP-1 RA combination use?
Benefits and challenges of AI-assisted screening for diabetic retinopathy and an overview of the eye health treatment landscape
*NEW* GIP infusion alone or in addition to semaglutide shows no improvement in glucose levels or body weight in T2D
Pooled analysis demonstrates the safety and efficacy of semaglutide among people with CKD also on dialysis
GLP-1 RA-based therapies and impact fertility, pregnancy, and early-onset T2D in women

Diabetes Technology Highlights

CGM and DGK: Dr. Bergenstal highlights technology-enabled improvements in T1D and T2D management
Expanding the horizons of MiniMed 780G: Evidence supports use in children, pregnancy, and for T2D
Dexcom COO Mr. Jake Leach spotlights CGM as a tool for reducing diabetes complications and enhancing therapy optimization
Roche’s Accu-Chek SmartGuide CGM: Real-world data (n=249) shows significant reduction (20%) in nocturnal hypoglycemic events with Night Low Predict feature
Three years of MiniMed 780G: Durable glycemic outcomes, reduced burden, and strengthened patient confidence
Glycemic improvements with Tandem’s Control-IQ at 12 months maintained at 24 months
Safety and accuracy of CGM for inpatient DKA management compared to hourly POC testing
International RCT finds CGM reduces risk of large-for-gestational-age infants in women with GDM
Automation in complexity: MiniMed 780G shows strength in T2D and other populations
A look to the FDA’s iCGM requirements: Evolving the minimum expectations for CGM market authorization in the EU
Defining provider roles in diabetes technology: The University of Leicester’s four-level competency framework
EASD Expert Session with Prof. Sabine Hofer and Dr. Amit Gupta: Education, reimbursement, and safety remain central to diabetes technology adoption across global settings
Risk factors for severe hypoglycemia in older adults: Insights from the iNPHORM study
Control-IQ in focus: A review of clinical strategies and 2025 OUS software updates
Medtronic shares clinical pearls for using smart MDI: Improving outcomes and simplifying decision making
Evidence supports benefit of CGM for reduction of severe, recurrent hypoglycemia
Trust as the cornerstone: CGM, AID, and AI in the next era of diabetes care
Diabetes technology for pregnancy: Bridging gaps between evidence and guidelines
Exercise and AID: Insights from the RAPPID study on hypoglycemia risk
GRACE and DipGluMo show the huge power of CGM’s role in GDM management
MiniMed 780G vs. Control-IQ: Handling unannounced meal in adolescents with T1D
New insights in glycemic management: Sleep duration, pregnancy, and a head-to-head comparison of three CGMs during exercise
*NEW* Insulet-sponsored symposium emphasizes scalable onboarding strategies and real-world outcomes with Omnipod 5 in T1D
*NEW* CGM use in hospitals: Clinical benefits and implementation challenges
*NEW* CGM as a routine for T2D: Evidence from RCTs, real-world data, and case studies
*NEW* Nationwide French data highlight durability and glycemic gains associated with AID use
*NEW* CamAPS FX and Control-IQ improve glycemia and neonatal outcomes vs. MiniMed 780G in pregnant women with T1D; strong outcomes across all systems

Diabetes Big Picture Highlights

CKD and T1D: Profs. Heerspink and Rossing argue status quo must change
Vienna welcomes nearly 13,500 participants with diabetes posters spotted in airport, buildings, and subways
Prof. Chantal Mathieu delivers most-valuable EASD Presidential Address, extolling vision for personalized, global diabetes care
Under promise and over deliver: Dr. Dan Drucker on his philosophy for scientific research
57th Claude Bernard Lecture by the esteemed Professor Andrew Hattersley focuses on “precision diabetes”: Learning from the rare and applying to the common
Novel diabetes subgroup classifications and optimized treatment plans based on glucose variability patterns from CGM data
Fructose consumption may play a key role in the development of MASLD
Exhibit Hall opens with high energy, featuring aromatic coffee stations, free lipid tests, and photobooths
An early look into the Breakthrough T1D-led early-stage T1D screening consensus document: Recommendations on who, what, when, where, how
Prof. Mikael Rydén receives the Camillo Golgi Prize for expanding knowledge of white adipose tissue and its role in diabetes
19th Albert Renold Lecture: Prof. Raphael Scharfmann on pancreatic development as a key to discover unexpected treatments of diabetes
EASD draft guidelines aim to bring diabetes distress assessment and management into routine care
Global analysis finds that diabetes is the largest contributor to sugar-sweetened beverage-related deaths
Building the future of diabetes care: Prof. Tadej Battelino receives diaTribe Solvable Problems’ Vanguard Leadership Award
Systematic analysis of the Global Burden of Disease reports major large-scale findings on prediabetes prevalence from 1990 to 2023
60th Minkowski Lecture: Dr. Teresa Mezza on prioritizing the pancreas in T2D
Dr. Steven Kahn and Prof. Roy Taylor on new-age incretin therapies as a path to T2D remission
Hyperglycemic crises: Q&A offers insight into best practice guidelines on DKA management
EASD-CEDA Joint Symposium: Diabetic complications in the era of precision medicine
EASD Diabetes Global Impact Prize Lecture
Rethinking A1c: Genetics, aging, and CGM differences challenge the “one-size-fits-all”
C-peptide measurements to improve classifications of diabetes in routine clinical practice
Significant increases in dementia-related mortality in people with diabetes compared to those without
New insights into persistent and increasing burdens of diabetes morbidity
Higher A1c thresholds required to predict T1D progression in adults compared to children with positive islet autoantibody
“The era of diagnosis”: Survival rates for T1D increased over decades